Results 31 to 40 of about 208,963 (249)

Presentation of AIDS with Disseminated Cutaneous and Visceral Leishmaniasis in Iran

Case Reports in Infectious Diseases, 2015
Leishmaniasis is an infectious disease in form of visceral (VL), cutaneous (CL), and mucocutaneous (MCL) leishmaniasis. Immunocompromised patients have increased risk of Leishmania infection, especially in endemic areas for visceral leishmaniasis, where
Mohammadali Davarpanah, Masumeh Rassaei, Fatemeh Sari aslani   +2 more
doaj   +1 more source

Characterization of a municipality as free of canine visceral leishmaniasis in the context of One Health

Revista Brasileira de Parasitologia Veterinária, 2021
Dogs are the main urban reservoir of Leishmania infantum, the causative agent of visceral leishmaniasis (VL), which is transmitted by sand flies. In the state of Paraná, the first detection of a positive dog for VL was in 2014, this year Paraná lost free
Silvia Cristina Osaki, Ricardo Babinski Bregonde, Vinicius Dahm, Priscila Pereira, Claudomiro Postai, Monique Paiva de Campos, Fabiano Borges Figueiredo   +6 more
doaj   +1 more source

Uniting mathematics and biology for control of visceral leishmaniasis [PDF]

, 2015
The neglected tropical disease (NTD) visceral leishmaniasis (VL) has been targeted by the WHO for elimination as a public health problem on the Indian subcontinent by 2017 or earlier.
Adams, ER, De Vlas, SJ, Hollingsworth, TD, Le Rutte, EA, Medley, GF, Rock, KS   +5 more
core   +2 more sources

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Safer and more effective oral drugs are urgently required to treat visceral leishmaniasis (VL), a neglected parasitic disease that kills 20,000–40,000 people each year in parts of Asia, Africa, and Latin America.
S. Wyllie, S. Brand, Michael G. Thomas, M. De Rycker, C. Chung, Imanol Peña, Ryan P. Bingham, Juan A. Bueren-Calabuig, J. Cantizani, D. Cebrián, P. Craggs, L. Ferguson, P. Goswami, J. Hobrath, Jonathan R Howe, Laura Jeacock, E. Ko, J. Korczynska, Lorna M MacLean, Sujatha Manthri, M. Martínez, Lydia Mata-Cantero, S. Moniz, Andrea Nühs, Maria Osuna-Cabello, É. Pinto, Jennifer Riley, Sharon A Robinson, P. Rowland, Frederick R. C. Simeons, Y. Shishikura, D. Spinks, L. Stojanovski, John Thomas, S. Thompson, Elisabet Viayna Gaza, Richard J. Wall, F. Zuccotto, D. Horn, M. Ferguson, A. Fairlamb, J. Fiandor, Julio Martin, David W. Gray, T. Miles, I. Gilbert, K. Read, Maria Marco, P. Wyatt   +48 more
semanticscholar   +1 more source

Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. [PDF]

, 2013
Between 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed
Brooker, Simon J, Chappuis, François, Koech, Timothy, Kolaczinski, Jan H, Lokwang, Peter, Mueller, Yolanda K, Riongoita, Mark, Velilla, Elena   +7 more
core   +2 more sources

Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy

Frontiers in Immunology, 2019
Leishmaniasis is a parasitic disease of humans, highly prevalent in parts of the tropics, subtropics, and southern Europe. The disease mainly occurs in three different clinical forms namely cutaneous, mucocutaneous, and visceral leishmaniasis (VL).
A. Dayakar, S. Chandrasekaran, S. Kuchipudi, Suresh K. Kalangi   +3 more
semanticscholar   +1 more source

Treatment of visceral leishmaniasis [PDF]

International Journal of Infectious Diseases, 2001
Growing antimony resistance in patients with visceral leishmaniasis (VL) over last two decades, especially in Indian subcontinent, renders this cheap and easily available drug useless for a vast majority of patients. Use of the second line drug pentamidine isethionate, a toxic drug with declining efficacy, has largely been abandoned.
openaire   +4 more sources

Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda [PDF]

, 2007
BACKGROUND: In East Africa, visceral leishmaniasis (VL) is endemic in parts of Sudan, Ethiopia, Somalia, Kenya and Uganda. It is caused by Leishmania donovani and transmitted by the sandfly vector Phlebotomus martini.
A. Ocheng, AHLUWALIA, Alvar, Anoopa Sharma, BARNETT, Basimike, Bern, Bern, Boussery, Bucheton, Chappuis, Chappuis, D. T Worku, Elnaiem, Filmer, Gebre-Michael, Hamilton, Heisch, Iversen, J. H Kolaczinski, J. Kasimiro, Jahn, Mohamed, N. Kabatereine, Ngumbi, Perkins, R. Reithinger, RANJAN, Robert, RYAN, S. Brooker, Schaefer, Schenkel, Takken   +33 more
core   +3 more sources

Eliminating visceral leishmaniasis in South Asia: the road ahead

British medical journal, 2019
Suman Rijal and colleagues highlight lessons from a regional collaboration to eliminate visceral leishmaniasis and identify priorities for the post-elimination ...
S. Rijal, S. Sundar, D. Mondal, P. Das, J. Alvar, M. Boelaert   +5 more
semanticscholar   +1 more source

Epidemiology of visceral leishmaniasis [PDF]

Clinical Epidemiology, 2014
Leishmania species are the causative agents of leishmaniasis, a neglected tropical disease. These parasitic protozoans are usually transmitted between vertebrate hosts by the bite of blood sucking female phlebotomine sand flies. This review focuses on the two parasites causing most human visceral leishmaniasis (VL), which leads to substantial health ...
openaire   +5 more sources